Your search for ESKD returned 6 results

In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.

A study found no significant increased risks for death or major adverse cardiac events among infected patients with established chronic kidney disease or end-stage kidney disease.

Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.

In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.